First patient dosed with breast cancer treatment ABY-271
The first patient has been dosed in a Phase I clinical trial of breast cancer treatment ABY-271.
ABY-271 is a radiotherapeutic candidate being assessed as a potential treatment for HER2-positive metastatic breast cancer. The Phase I study evaluating the safety, tolerability and biodistribution of ABY-271 is a first-in-human open-label, two-stage, randomised trial being conducted in Sweden and Germany. The first patient was enrolled at Uppsala University Hospital in Sweden.
ABY-271 is an Affibody molecule that targets HER2-expressing tumours and is labelled with the radioisotope lutetium-177, which emits cytotoxic beta radiation, exerting irreversible damage to the tumour cells upon binding.
“This milestone is a testament to our team’s dedication and hard work to bring next-generation radiotherapeutics to patients in need of new treatment options,” said David Bejker, CEO of Affibody. “We believe ABY-271’s targeted mechanism has the potential to significantly improve the lives of patients battling metastatic breast cancer and we look forward to the study results with great excitement.”
Henrik Lindman, Associate Professor and Head of the Department of Hematology and Oncology at Uppsala University Hospital in Sweden, described a “significant unmet medical need for more effective and targeted treatments for cancer patients with advanced disease.”
“We are proud to be the first site to dose a patient with ABY-271,” Lindman added, “and look forward to continuing to collaborate with Affibody and the other clinics to rapidly enrol patients in this first-in-human trial.”
The first results from the study are expected later this year.
Bruno Quinney, Content Team, DDW
